Announcements

Medtronic Launches First-Of-Its-Kind mySentry™ Remote Glucose Monitor

January 4, 2012

MINNEAPOLIS – January 4, 2012 – Today, Medtronic, Inc. (NYSE:MDT) announced U.S. Food and Drug Administration (FDA) approval and U.S. market launch of the first-of-its-kind mySentry™ Remote Glucose Monitor, which allows a parent or caregiver to monitor from another room a patient’s MiniMed Paradigm® REAL-Time Revel™ System. The remote glucose monitor also marks the launch of a new category of Connected Care solutions that will provide people with diabetes and their caregivers convenient options to access their diabetes management information.

Medtronic Receives FDA Approval for Next Generation Professional Continuous Glucose Monitoring

November 22, 2011

MINNEAPOLIS – November 22, 2011 – Medtronic, Inc. (NYSE:MDT) today announced the Food and Drug Administration (FDA) approval of iPro®2, a next generation Professional continuous glucose monitoring (CGM) system and the latest in a series of recent diabetes technology approvals and innovations from the company. iPro2 simplifies Professional CGM and enables healthcare providers to obtain a more complete picture of glucose control for the patients they treat.  Professional CGM is used by healthcare providers to reveal low (hypoglycemia) and high (hyperglycemia) glucose excursions that can lead to the dangerous health complications of diabetes.  These excursions often go unnoticed with traditional A1C tests and standard glucose meter measurements.

Medtronic Begins Enrolling U.S. IDE Study of Enlite™ Sensor for Continuous Glucose Monitoring

November 9, 2011

MINNEAPOLIS – Nov. 9, 2011 – Medtronic, Inc. (NYSE: MDT) today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in adults with diabetes of its Enlite™ Sensor, the company’s latest innovation in continuous glucose monitoring (CGM) technology for people with diabetes. The study will evaluate Enlite, a glucose sensor for CGM designed to offer improved hypoglycemic detection and comfort compared to current CGM sensors. CGM provides a more complete picture of glucose control because it can reveal high and low glucose levels that periodic fingerstick testing might miss.

Medtronic Receives IDE Approval to Conduct Aspire In-Home Study of First Insulin Pump with Low Glucose Suspend for US Market

October 28, 2011

MINNEAPOLIS – October 28, 2011 – In our continued commitment to develop an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal in-home clinical trial protocol for the ASPIRE study of the MiniMed Paradigm® System featuring Low Glucose Suspend (LGS) automation. FDA approval of the IDE makes Medtronic’s ASPIRE study the first in-home pivotal trial of a closed loop system for Type 1 diabetes management. 

Medtronic Update on Insulin Pump Security

October 26, 2011

Medtronic takes patient safety and device security very seriously and we appreciate the security community bringing new information on the possibility of a cyber-attack on our insulin pumps. We have been increasing our focus on the prevention of tampering with our products and look forward to partnering with the security, healthcare and diabetes communities to develop ways to better protect patients from the risk of tampering, which is necessary to keep pace with a new and rapidly evolving technology landscape.

We have taken a number of steps to address this matter including conducting an in-depth risk/benefit analysis to clearly assess the potential risk, evaluating the best encryption and security technologies for incorporation into our products and design process, and finally, committing to establish an industry working group that engages relevant stakeholders from the diabetes, healthcare and security community to develop new approaches and best practices to device security.

Because insulin pumps are widely used by patients with diabetes for tight blood sugar control and lifestyle flexibility, we are also working to assure both patients and doctors that at this time we believe that the risk is low and the benefits of the therapy outweigh the risk of an individual criminal attack.

View all Announcements >

Media Inquiries

For media inquiries pertaining to the Diabetes business of Medtronic, please contact:

Amanda Sheldon
Director of Public Relations
818-576-4826
amanda.sheldon@medtronic.com

For all other media inquiries please select the appropriate Global Public and Media Relations contact